Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis

Exclusion Criteria

• •Any clinically significant disease or disorder
• •Patients with other latent or chronic infections or at risk of infection within 90 days before Visit 2
• •An acute exacerbation or acute respiratory infection (upper or lower) requiring oral steroids or antibiotics within 30 days prior to Visit 2
• •An FEV1 of \<30% of predicted normal at Visit 1
• •Patients who have received live or live-attenuated vaccine in the 2 weeks prior to dosing (Visit 2)
• •Concomitant diagnosis of significant pulmonary disease other than bronchiectasis or COPD, including symptomatic asthma and allergic bronchopulmonary aspergillosis
• •Bronchiectasis associated with a generalised immunodeficiency disorder, where manifestations other than bronchiectasis predominate